22157.jpg
CD70 Targeting Therapies Clinical Trials Insight 2025: 20+ CD70 Targeting Therapies In Clinical Trials
31 janv. 2025 05h00 HE | Research and Markets
Dublin, Jan. 31, 2025 (GLOBE NEWSWIRE) -- The "CD70 Targeting Therapies Clinical Trials & Market Opportunity Insight 2025" report has been added to ResearchAndMarkets.com's offering. CD70...
logo.jpg
Processa Pharmaceuticals Announces Formation of Oncology Advisory Board with Renowned Key Opinion Leaders
01 nov. 2023 08h15 HE | Processa Pharmaceuticals, Inc.
Company To Leverage World-Class Oncology Advisory Board in the Design of Oncology Trial Protocols, Including the Anticipated Phase 2 Trial for NGC-Cap HANOVER, MD, Nov. 01, 2023 (GLOBE NEWSWIRE) --...
GeoVax.png
GeoVax Completes Enrollment of Phase 2 Trial for Next-Generation COVID-19 Vaccine Booster
11 sept. 2023 09h00 HE | GeoVax, Inc.
Multi-antigen Vaccine Designed to Protect Against Evolving SARS-CoV-2 Variants ATLANTA, GA, Sept. 11, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology...
Logo.png
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
12 juin 2023 07h00 HE | BioRestorative Therapies, Inc
--Clinical data expected to be reviewed by independent data safety monitoring board (DSMB) as to initial safety dosing profile of BRTX-100--  MELVILLE, N.Y., June 12, 2023 (GLOBE NEWSWIRE) --...
VIR_logo_large.jpg
Vir Biotechnology Announces First Patient Dosed in the Phase 2 SOLSTICE Trial Evaluating VIR-2218 and VIR-3434 for the Treatment of Chronic Hepatitis D Virus Infection
22 sept. 2022 08h00 HE | Vir Biotechnology, Inc.
– Impacting more than 12 million people globally, HDV is the most aggressive form of viral hepatitis – – Novel combination strategy designed toreduce HDV viremia and block viral entry – SAN...
Moonlake logo.png
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
12 mai 2022 07h00 HE | MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics starts Phase 2 trial of the Nanobody® Sonelokimab in patients with moderate-to-severe hidradenitis suppurativa First Phase 2 trial in hidradenitis suppurativa using the...
Survival Benefit Achieved by Combining Rhu-pGSN with Meropenem
BioAegis Therapeutics Announces Study Indicating Gelsolin Treatment Improves Survival and Reduces Lung Injury in Antibiotic Resistant Pneumonia
03 sept. 2020 21h42 HE | BioAegis Therapeutics
MORRISTOWN, N.J., Sept. 03, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
AzurRx_Logo_CMYK.jpg
AzurRx BioPharma Announces First Patients Dosed in Phase 2b OPTION 2 Clinical Trial of MS1819 in Cystic Fibrosis
13 août 2020 08h00 HE | AzurRx BioPharma, Inc.
First three patients enrolled in dose escalation trial using delayed-release enteric capsulesTopline data expected in 1H 2021 NEW YORK, Aug. 13, 2020 (GLOBE NEWSWIRE) --  AzurRx BioPharma, Inc....
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Initiates Phase 2 Clinical Trial of Its Inflammation Regulator, Gelsolin, for COVID-19 Treatment
05 août 2020 18h16 HE | BioAegis Therapeutics
MORRISTOWN, N.J., Aug. 05, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., a clinical stage, private company developing therapies for infectious, inflammatory and degenerative diseases through...
BioAegis Therapeutics LOGO 2.5 x 5 150 pixel.jpg
BioAegis Therapeutics Receives Approval to Proceed with Phase 2 Trial of its Gelsolin COVID-19 Treatment
15 juil. 2020 13h34 HE | BioAegis Therapeutics
MORRISTOWN, N.J., July 15, 2020 (GLOBE NEWSWIRE) -- BioAegis Therapeutics Inc., announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products (AEMPS) for...